Integrin subunit alpha V (ITGAV) mRNA (ITGAV mRNA)

Integrin subunit alpha V (ITGAV) mRNA is the transcript encoding the alpha V subunit of the integrin receptor family, also known as CD51 [UniProt]. This subunit is unique in its ability to heterodimerize with five different beta subunits (β1, β3, β5, β6, and β8), forming receptors that mediate cell-matrix adhesion and signaling [NCBI Gene]. These integrins are essential for the activation of latent TGF-beta, a process critical for tissue fibrosis and tumor-mediated immunosuppression [PubMed: 28234337]. ITGAV mRNA is frequently overexpressed in various malignancies and fibrotic conditions, where it drives angiogenesis, epithelial-mesenchymal transition (EMT), and metastasis [PubMed: 30104719]. Therapeutic targeting of ITGAV mRNA using RNA interference (RNAi) technologies, such as the dual-targeting siRNA STP705, allows for the simultaneous knockdown of all alpha V-containing integrins [Sirnaomics]. This approach is being investigated for its potential to treat solid tumors and fibrotic skin disorders by disrupting multiple pathological pathways at the transcriptional level [ClinicalTrials.gov]. By silencing the mRNA, researchers aim to achieve a more comprehensive inhibition of alpha V-mediated signaling than is possible with subunit-specific antibodies [PubMed: 23536546]. Clinical development of these RNA-based therapies focuses on optimizing delivery systems to ensure efficient uptake in target tissues while minimizing systemic toxicity [PubMed: 32157240].

Other names

CD51 mRNAVitronectin receptor alpha subunit mRNAMSK8 mRNAVNRA mRNAVTNR mRNA

RNA interference (siRNA-mediated degradation of ITGAV mRNA)